Medical Devices

With record 2025 revenue and a dominant hold on the gene therapy market, Cryoport's strategic investments pave a path toward profitability.

Immunome announces stellar Phase 3 data for its desmoid tumor drug, varegacestat, and details a robust, well-funded ADC pipeline aimed at solid tumors.

The nation's leading aesthetic provider launches a Salmon DNA Facial, XTherma, and NAD+ injections, betting on the science of regenerative beauty.

The acquisition signals a major trend: investors are banking on professional skincare and the mature consumer. Here's what the deal means for the industry.

The D.C. transplant institute surpasses a historic milestone, pioneering new tech and giving thousands a second chance at life amid a national organ shortage.

Spryte Medical's new trial is testing a device that gives surgeons a real-time, microscopic view inside brain arteries for the first time.

A new report from the nation's largest eye care provider boasts stellar results. We dig into the data, the industry trends, and what it means for patients.

A unique $4M award program aims to solve a critical funding gap, accelerating high-risk, high-reward cancer therapies from academic labs to patients.

PathAI's PathAssist Derm receives FDA Breakthrough designation, promising to enhance accuracy and speed in diagnosing the most common cancer in the U.S.

A new partnership gives thousands of young athletes in Las Vegas free recovery tech while a unique manufacturing model boosts the local economy.

With its pivotal trial fully enrolled, Liberate Medical’s VentFree device aims to shorten ICU stays, reduce complications, and cut healthcare costs.

From the surface of Mars to Earth's most advanced labs, space-tested positioning tech is enabling breakthroughs in semiconductors, photonics, and biotech.

A novel sputum test could end the trial-and-error approach for millions with chronic respiratory disease, promising a new era of personalized medicine.

A new deal brings Nanox's low-radiation, cost-effective Nanox.ARC to orthopedic clinics, aiming to reshape point-of-care diagnostics in the region.

A novel drug delivery system could revolutionize Alzheimer's treatment, and Acumen Pharmaceuticals is leading the charge with its targeted therapy.

After a kidney trial setback, CalciMedica's lead drug Auxora shows strong promise for acute pancreatitis, but a tight cash runway looms over its future.

A novel inhaled RNA therapy for a specific group of cystic fibrosis patients gains EMA fast-track status, promising accelerated access to new treatment.

With its SMA drug stalled by a factory inspection, Scholar Rock secures major financing and signals a clear path to a transformative market debut in 2026.

New research reveals a media blind spot for hearing loss, fueling stigma. A new campaign aims to change the picture and normalize hearing aids for millions.

Esperion's $75M+ deal for Corstasis and its novel nasal diuretic, Enbumyst, targets a $4B market and a new era of at-home edema management.